Valeant CEO Says He Was 'Too Aggressive' On Drug Prices
The outgoing CEO of Valeant Pharmaceuticals International Inc. told a skeptical U.S. Senate panel Wednesday that he and the company were "too aggressive" when increasing drug prices, as hedge fund manager...To view the full article, register now.
Already a subscriber? Click here to view full article